Remarkably, populations of CD45+CD11b+ cells (including macrophages), but not NK cells, were increased in tumors treated with Lip-MSA-IL-2 and TAB004, suggesting a key role for CD45+CD11b+ cells (including macrophages) in the limitation of tumor progression in vivo. This evidence concerns the gene IL2 and neoplasm.